Commentary on the Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials

There is increasing concern that reports of industry-sponsored research, such as “Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials” by Robinson and et al. (found on page 15), may present an overly positive description of the research findings. Editorial oversight can help to ensure a more balanced presentation of the results, although on this occasion I have been involved in consulting with the sponsor of this research (Bristol-Myers Squibb), and also working on secondary analyses of this data set. For this reason, Psychopharmacology Bulletin invited Daniel J. Carlat, MD, Assistant Clinical Professor of Psychiatry at Tufts University School of Medicine, to write this commentary.